Cyclerion Therapeutics Inc (CYCN)
2.67
-0.08
(-2.91%)
USD |
NASDAQ |
May 31, 16:00
2.94
+0.27
(+10.11%)
Pre-Market: 20:00
Cyclerion Therapeutics Enterprise Value: 0.9779M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 0.9779M |
| May 30, 2024 | 1.178M |
| May 29, 2024 | 1.178M |
| May 28, 2024 | 1.178M |
| May 24, 2024 | 1.703M |
| May 23, 2024 | 1.703M |
| May 22, 2024 | 1.078M |
| May 21, 2024 | 0.803M |
| May 20, 2024 | 1.298M |
| May 17, 2024 | 1.428M |
| May 16, 2024 | 1.428M |
| May 15, 2024 | 1.503M |
| May 14, 2024 | 1.503M |
| May 13, 2024 | 2.178M |
| May 10, 2024 | 2.178M |
| May 09, 2024 | 1.803M |
| May 08, 2024 | 1.473M |
| May 07, 2024 | 1.403M |
| May 06, 2024 | 1.403M |
| May 03, 2024 | 1.690M |
| May 02, 2024 | 1.353M |
| May 01, 2024 | 1.903M |
| April 30, 2024 | 1.378M |
| April 29, 2024 | 2.003M |
| April 26, 2024 | 1.628M |
| Date | Value |
|---|---|
| April 25, 2024 | 1.903M |
| April 24, 2024 | 1.228M |
| April 23, 2024 | 1.928M |
| April 22, 2024 | 1.928M |
| April 19, 2024 | 3.053M |
| April 18, 2024 | 2.348M |
| April 17, 2024 | 2.348M |
| April 16, 2024 | 2.253M |
| April 15, 2024 | 2.603M |
| April 12, 2024 | 2.728M |
| April 11, 2024 | 1.927M |
| April 10, 2024 | 2.053M |
| April 09, 2024 | 1.828M |
| April 08, 2024 | 2.303M |
| April 05, 2024 | 2.553M |
| April 04, 2024 | 2.778M |
| April 03, 2024 | 2.203M |
| April 02, 2024 | 2.203M |
| April 01, 2024 | 1.978M |
| March 28, 2024 | 0.5544M |
| March 27, 2024 | 0.2502M |
| March 26, 2024 | 0.2497M |
| March 25, 2024 | 0.1228M |
| March 22, 2024 | 0.1736M |
| March 21, 2024 | 0.5544M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-67.59M
Minimum
Nov 15 2019
320.33M
Maximum
Jun 20 2019
40.02M
Average
12.29M
Median
Aug 11 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 803.37B |
| iBio Inc | 28.91M |
| AbbVie Inc | 340.70B |
| Agile Therapeutics Inc | -0.1399M |
| NovaBay Pharmaceuticals Inc | 4.387M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.542M |
| Total Expenses (Quarterly) | 1.618M |
| EPS Diluted (Quarterly) | -0.62 |
| Earnings Yield | -16.10% |
| Normalized Earnings Yield | -891.50 |